Apo CI

GWB-4F32B8

Full length native protein (purified) (Human)

Specific for Human Apo CI. No cross reactions with Apo AI Apo AII Apo B-100 Apo CII Apo CIII and Apo E.

Secreted

Sepharose affinity column. Storage

Use at an assay dependent dilution.
ELISA: 1/2 500 - 1/20 000. EIA: Use at an assay dependent dilution. IA: Use at an assay dependent dilution. WB: 1/2 500 - 1/20 000. Predicted

Secreted The protein encoded by this gene is a member of the apolipoprotein C1 family. This gene is expressed primarily in the liver and it is activated when monocytes differentiate into macrophages. A pseudogene of this gene is located 4 kb downstream in the same orientation on the same chromosome. This gene is mapped to chromosome 19 where it resides within a apolipoprotein gene cluster. Alternatively spliced transcript variants have been found for this gene but the biological validity of some variants has not been determined. Apolipoprotein C-I appears to modulate the interaction of APOE with beta-migrating VLDL and inhibit binding of beta-VLDL to the LDL receptor-related protein. At least 9 distinct polymorphic forms of apolipoproteins are known. The apolipoproteins act as stabilizers of the intact lipoprotein particles. Quantitative measurements of HDL LDL and VLDL particles in human serum are often used to estimate an individuals\' relative risk of coronary heart disease. In addition quantitative immunological measurements of certain apolipoproteins (especially A-1 and B) have been suggested to be more accurate estimators of coronary heart disease than measurements of lipoprotein particles (especially HDL and LDL).

Secreted.

Apo-CI makes up about 10% of the protein of the VLDL (very low density lipoprotein) and 2% of that of HDL (high density lipoprotein).